PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
复制标题
PSA 达到最低点的时间作为去势抵抗性前列腺癌一线多西紫杉醇治疗的预后因素：在中国前列腺癌联盟患者中进行的多中心验证
DOI：
10.1016/j.urolonc.2019.07.014
复制
发表时间：
2020-01-01
影响因子：
2.7
通讯作者：
Li, Lei
中科院分区：
文献类型：
--
作者：
Pei, Xinqi;Wu, Kaijie;Li, Lei
目的：在中国，以多西他赛为基础的化疗仍然是转移性去势抵抗性前列腺癌（mCRPC）患者的一线治疗方法。我们先前已表明，前列腺特异性抗原（PSA）达到最低值的时间（TTN）是中国西北某单中心患者的一个重要预后因素。在本研究中，我们对TTN在其他接受多西他赛治疗的中国mCRPC患者中的预后作用进行了多中心验证。
材料和方法：数据来自2007年1月至2018年10月在中国11家中国前列腺癌协作组（Chinese Prostate Cancer Consortium）成员医院接受多西他赛化疗的170例符合条件的中国患者。TTN定义为从化疗开始到治疗期间PSA水平达到最低值的时间。采用多变量Cox回归模型和Kaplan - Meier分析来预测总生存期（OS）和无进展生存期（PFS）。
结果：与TTN＜15周的患者相比，TTN≥15周的患者具有更长的OS和PFS（分别为43个月对15个月，P＜0.001；24个月对6个月，P＜0.001）。此外，TTN≥15周且PSA最低值≤0.2 ng/mL的患者比TTN＜15周且PSA最低值＞0.2 ng/mL的患者具有更好的OS和PFS。
结论：在这项多中心验证研究中，TTN和PSA最低值仍然是预测接受mCRPC化疗的中国男性治疗结果的重要预后标志物。（C）2019爱思唯尔公司。保留所有权利。
Objective: Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China. We have previously shown that time to nadir (TTN) of prostate-specific antigen (PSA) is an important prognostic factor in patients from a single center in Northwestern China. In this study, we performed a multicenter validation of the prognostic role of TTN in additional Chinese patients with mCRPC receiving docetaxel treatment.Materials and methods: The data were gathered from 170 eligible Chinese patients who received docetaxel chemotherapy from January 2007 to October 2018 in 11 Chinese Prostate Cancer Consortium member hospitals in China. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival (OS) and progression-free survival (PFS).Results: Patients with a TTN >= 15 weeks had a longer OS and PFS compared to those with a TTN < 15 weeks (43 vs. 15 months, P < 0.001; 24 vs. 6 months, P < 0.001, respectively). In addition, Patients with a TTN >= 15 weeks and PSA nadir = 15 weeks.Conclusion: In this multicenter validation study, TTN and PSA nadir remain important prognostic markers in predicting therapeutic outcomes in Chinese men who receive chemotherapy for mCRPC. (C) 2019 Elsevier Inc. All rights reserved.